Bos Michael J, de Korte-de Boer Dianne, Alzate Sanchez Ana Maria, Duits Annelien, Ackermans Linda, Temel Yasin, Absalom Anthony R, Buhre Wolfgang F, Roberts Mark J, Janssen Marcus L F
Department of Anesthesiology and Pain Medicine, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.
Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands.
J Clin Med. 2021 Apr 7;10(8):1557. doi: 10.3390/jcm10081557.
Subthalamic nucleus (STN) deep brain stimulation (DBS) has become a routine treatment of advanced Parkinson's disease (PD). DBS surgery is commonly performed under local anesthesia (LA) to obtain reliable microelectrode recordings. However, procedural sedation and/or analgesia (PSA) is often desirable to improve patient comfort. The impact of PSA in addition to LA on outcome is largely unknown. Therefore, we performed an observational study to assess the effect of PSA compared to LA alone during STN DBS surgery on outcome in PD patients.
Seventy PD patients (22 under LA, 48 under LA + PSA) scheduled for STN DBS implantation were included. Dexmedetomidine, clonidine or remifentanil were used for PSA. The primary outcome was the change in Movement Disorders Society Unified Parkinson's Disease Rating Score III (MDS-UPDRS III) and levodopa equivalent daily dosage (LEDD) between baseline, one month before surgery, and twelve months postoperatively. Secondary outcome measures were motor function during activities of daily living (MDS-UPDRS II), cognitive alterations and surgical adverse events. Postoperative assessment was conducted in "on" stimulation and "on" medication conditions.
At twelve months follow-up, UPDRS III and UPDRS II scores in "on" medication conditions were similar between the LA and PSA groups. The two groups showed a similar LEDD reduction and an equivalent decline in executive function measured by the Stroop Color-Word Test, Trail Making Test-B, and verbal fluency. The incidence of perioperative and postoperative adverse events was similar between groups.
This study demonstrates that PSA during STN DBS implantation surgery in PD patients was not associated with differences in motor and non-motor outcome after twelve months compared with LA only.
丘脑底核(STN)深部脑刺激(DBS)已成为晚期帕金森病(PD)的常规治疗方法。DBS手术通常在局部麻醉(LA)下进行,以获得可靠的微电极记录。然而,程序镇静和/或镇痛(PSA)通常有助于提高患者舒适度。除LA外,PSA对手术结果的影响很大程度上未知。因此,我们进行了一项观察性研究,以评估在STN DBS手术中,与单独使用LA相比,PSA对PD患者手术结果的影响。
纳入70例计划进行STN DBS植入的PD患者(22例接受LA,48例接受LA + PSA)。右美托咪定、可乐定或瑞芬太尼用于PSA。主要结局是手术前1个月基线与术后12个月之间运动障碍协会统一帕金森病评定量表III(MDS-UPDRS III)和左旋多巴等效日剂量(LEDD)的变化。次要结局指标是日常生活活动中的运动功能(MDS-UPDRS II)、认知改变和手术不良事件。术后评估在“开启”刺激和“开启”药物治疗状态下进行。
在12个月的随访中,LA组和PSA组在“开启”药物治疗状态下的UPDRS III和UPDRS II评分相似。两组的LEDD降低程度相似,通过Stroop色词测验、连线测验-B和语言流畅性测量的执行功能下降程度相当。两组围手术期和术后不良事件的发生率相似。
本研究表明,与仅使用LA相比,PD患者在STN DBS植入手术中使用PSA在12个月后与运动和非运动结局的差异无关。